Streetbeat News

EWTX

Edgewise Therapeutics, Inc.

https://www.edgewisetx.com

Industry

Biotechnology

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

RBC Capital analyst Leonid Timashev maintains an Outperform rating on Edgewise Therapeutics (NASDAQ:EWTX) and raises the price target from $28 to $32.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 3:48 pm

Truist Securities analyst Srikripa Devarakonda has reaffirmed a Buy rating on Edgewise Therapeutics (NASDAQ:EWTX) and maintained a price target of $25.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 5:19 pm

Wedbush analyst Laura Chico reiterated an Outperform rating on Edgewise Therapeutics (NASDAQ:EWTX) and maintained a $26 price target.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 2:19 pm

RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on Edgewise Therapeutics (NASDAQ:EWTX) and maintained a $28 price target.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 3:12 pm

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Edgewise Therapeutics (EWTX) with an Overweight rating and a price target of $48.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 10:22 am

Edgewise Therapeutics (NASDAQ:EWTX) reported Q4 earnings with an EPS of $-0.47, missing estimates by 9.3% compared to the expected $-0.43. Revenue remained unchanged from the previous year. This follows a pattern from the last quarter where the company also missed EPS estimates, leading to a 3.67% drop in share price the following day.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 2:30 pm

Edgewise Therapeutics (NASDAQ:EWTX) reported a Q4 EPS loss of $(0.47), missing the consensus estimate of $(0.43) by 9.3%. This represents a 51.61% increase in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:09 pm

Edgewise Therapeutics (NYSE:EWTX) has seen a significant decrease in short interest, with a 58.78% drop since the last report. The current short interest stands at 8.17 million shares, representing 15.01% of the float. It would take about 7.63 days for traders to cover their short positions. While a decrease in short interest can indicate a more bullish sentiment, it does not necessarily predict a near-term rise in stock price. Edgewise has a higher short interest compared to its peers, with the average being 11.57%.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 8:30 pm

Insiders at Tile Shop Holdings, Edgewise Therapeutics, and Wolfspeed have made notable stock purchases. Pleasant Lake Partners LLC bought 14,600 shares of Tile Shop at $6.73 each, while Edgewise's Peter A Thompson acquired 454,545 shares at $11.00 each following a $240 million offering. Wolfspeed's Thomas H Werner purchased 683 shares at $32.05 each amid an extended wafer supply agreement with Infineon.

Portfolio Pulse from Avi Kapoor

January 26, 2024 | 11:34 am

TransCode Therapeutics, Inc. (RNAZ) shares fell by over 24% after pricing a common stock offering at $1.22 per share. Other stocks moved in Friday's mid-day session with notable gainers including Charge Enterprises (CRGE), Kaman Corporation (KAMN), and Mesa Air Group (MESA), among others. Losers included C3is Inc. (CISS), Azitra, Inc. (AZTR), and iRobot Corporation (IRBT). The market also reacted to various company announcements such as acquisitions, earnings reports, and analyst upgrades or downgrades.

Portfolio Pulse from Avi Kapoor

January 19, 2024 | 6:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.